- About Overview
- Honors and Awards
- Facts and Figures
- Support the School
- Contact Us
- Dean’s Office
- Dean’s Office Overview
- Assistant Deans
- Associate Deans
- Education Unit
- Office of Academic Affairs
- Office of Administration
- Org chart
- Patient Care
Hiding in plain sight
School of Pharmacy scientists engineer drug delivery device that treats glaucoma directly inside the eye
By Levi Gadye / Tue Nov 21, 2017
Glaucoma, which affects over 60 million people worldwide, can seem easy to treat: medicated eye drops can be used to ease the buildup of fluid in the eye that underlies the condition. If glaucoma is caught early, eye drops can prevent irreversible blindness.
But prescription eye drops aren’t the perfect solution for glaucoma. Many elderly patients who suffer from glaucoma struggle to take their eye drops on time, which is required up to three times a day. And even when patients comply with this intensive eye drop schedule, much of the medication drains into the patient’s blood, missing its target inside the eye.
Those problems could be part of the past, thanks to a device developed in the lab of Tejal Desai, PhD. The tiny implant promises to simplify how glaucoma drugs are administered, making life easier for aging patients.
Desai, who is chair of the Department of Bioengineering and Therapeutic Sciences, a joint department of the UCSF Schools of Pharmacy and Medicine, recently reported her lab's success using the implant to reduce eye pressure in animals in the Journal of Controlled Release. The paper’s first author, Jean Kim, is a PhD student in the Desai Lab.
Journal Citation: Kim J, Kudisch M, da Silva NRK, Asada H, Aya-Shibuya E, Bloomer MM, Mudumba S, Bhisitkul RB, Desai TA (2018), “Long-term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma agent,” Journal of Controlled Release, 269: 45-51(published online Nov. 7, 2017), doi: 10.1016/j.jconrel.2017.11.008.
Drug implant dissolves to treat glaucoma
Recognizing the need for a drug delivery method that removes the fuss for patients, the researchers toyed with degradable materials that would slowly release the medication while dissolving in the eye. They settled on a “sandwich” of biodegradable films surrounding an anti-glaucoma drug. Using this design, “we can load enough drug in the tiny device to last over six months,” says Desai.
The researchers implanted the drug-releasing devices and measured eye pressure on a weekly basis for 24 weeks. Beyond some rare and minor complications, the device successfully reduced eye pressure in the animals for the duration of the study.
“While there have been important advances in eye drop formulations, our device substantially reduces the burden of patient compliance in a safe and effective way,” Desai says.
Desai is hopeful that her lab’s device will soon improve outcomes for patients. “Next steps will involve scaling up, developing device fabrication procedures that comply with current good manufacturing practices, and testing the device in larger animals, before moving on to clinical trials,” she says.
About the School: The UCSF School of Pharmacy is a premier graduate-level academic organization dedicated to improving health through precise therapeutics. It succeeds through innovative research, by educating PharmD health professional and PhD science students, and by caring for the therapeutics needs of patients while exploring innovative new models of patient care. The School was founded in 1872 as the first pharmacy school in the American West. It is an integral part of UC San Francisco, a leading university dedicated to promoting health worldwide.